Cytotoxic and genotoxic effects of some substituted tetrazolo[1,5-c] quinazolines

Neoplasma

Volumn 51, Issue 6, 2004, Pages 436-441

  Jantova S ^a   Theiszova M ^a   Mikulasova M ^a  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Antibacterial activity; Cancer cell line B16; Cell proliferation; Cytotoxicity; Genotoxicity; Quinazoline derivatives

Indexed keywords

9 BROMO 5 MORPHOLINOTETRAZOLO[1,5 C]QUINAZOLINE; AMPICILLIN; QUINAZOLINE DERIVATIVE; TETRAZOLO[1,5 C]QUINAZOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER CELL CULTURE; CANCER SCREENING; CELL PROLIFERATION; CYTOSTASIS; CYTOTOXICITY; DERIVATIZATION; DNA REPAIR; ENZYME ACTIVITY; GENOTOXICITY; GROWTH INHIBITION; IC 50; METABOLIC ACTIVATION; MOUSE; NONHUMAN; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 11144223258     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ALBANELL J, ROJO F, AVERBUCH S, FEYEREISLOVA A, MASCARO JM et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 1: 110-24.
2. BASELGA J, AVERBUCH SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60: 33-42.
3. BERKHIT AA, HABIB NS, EL-DIN A, BERKHIT A. Synthesis and antimicrobial evaluation of chalcone and syndrome derivatives of 4(3H)-quinazolinone. Boll Chim Farm 2001; 140: 297-301.
4. BENNING CM, KYPRIANOU N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res 2002; 62(2): 597-602.
5. BOWMAN KJ, NEWELL DR, CALVERT AH, CURTIN NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001; 84: 106-112.
6. CALLAIS F, MIN S, GIORGI-RENAULT S, FESTY B. Structure-activity relationships of a series of antitumoral 5,8-quinazolinediones in mutagenicity studies. Mutat Res 1991; 261: 51-56.
7. EISA HM. Fused pyrimidines. Synthesis of new derivatives of potential diuretic activity. Boll Chim Farm 1996; 135: 585-590.
8. HIRATA A, OGAWA S, KOMETANI T, KUWANO T, NAITO S et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560.
9. CHAO Q, DENG L, SHIH H, LEONI LM, GENINI D et al. Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. J Med Chem 1999; 42: 3860-3873.
10. ISHIHARA T, KOHNO K, USHIO S, IWAKI K, IKEDA M, KURIMOTO M. Tryptanthrin inhibits nitric oxide and prostaglandin E(2) synthesis by murine macrophages. Eur J Pharm 2000; 407: 197-204.
11. JACKMAN AL, TAYLOR GA, GIRSON W, KIMBELI R, BROWN M et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent of L1210 tumor cell growth in vitro and in vivo: A new agent dor clinical study. Cancer Res 1991; 51: 5579-5586.
12. JANTOVÁ S, HUDECOVÁ D, STANKOVSKÝ Š, ŠPIRKOVÁ K, RUŽEKOVÁ L'. Antibacterial effect of substituted 4-quinazolylhydrazines and their arylhydrazones determined by modified microdilution method. Folia Microbiol 1995; 40: 611-614.
13. JANTOVÁ S, RUŽEKOVÁ L', ŠPIRKOVÁ K, STANKOVSKÝ Š. Cytotoxic effect of substituted tetrazolo[1,5-c] quinazolines on HeLa cells. Biology 1997; 52: 445-450.
14. JANTOVÁ S, RUŽEKOVÁ L', STANKOVSKÝ Š, ŠPIRKOVÁ K. Antiproliferation activity and the mechanism of action of 9-bromo-5-morpholino-tetrazolo[1,5-c] quinazoline - potentional anticancer drug. Neoplasma 1997; 44: 240-246.
15. JANTOVÁ S, URBANČÍKOVÁ M, MALIAR T, MIKULÁŠOVÁ M, RAUKO P et al. Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of action cytoskeleton. Neoplasma 2001; 1: 52-60.
16. JANTOVÁ S, ČIPÁK L', SLAMEŇOVÁ D, HORVÁTH V, RAUKO P. Induction of cytotoxicity and ssDNA breaks by 9-bromo-5-morpholino-tetrazolo[1,5-c]quinazoline in tumor cells cultured in vitro. Toxicol in Vitro 2003; 17: 457-463.
17. JIMENEZ MA, TORROELLA M, FERNANDEZ SI, PELLON R. Studies on mutagenicity of 2bronchodilator under development in Cuba. Mutat Res 1983; 3-4: 225-235.
18. KAYE SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78; 1-7.
19. LABUDA J, BUČKOVÁ M, JANTOVÁ S, ŠTEPÁ NEK I, SURUGIU I et al. Modified screen-printed electrodes for the investigation of the interaction of non-electroactive quinazoline derivatives with DNA. Fresenius J Analytic Chem 2000; 367: 364-368.
20. LASZTOCZI B, KOVACS R, NYIKOS L, KARDOS J. A glutamate receptor subtype antagonist inhibits seizures in rat hippocampal slices. Neuroreport 2002; 13: 351-356.
21. LICHTNER RB, MENRAD A, SOMMER A, KLAR U, SCHNEIDER MR. Signaling-inactive epidermal growth factor receptor/ligand complex in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001; 61: 5790-5795.
22. LOPEZ-FARRE A, RODRIGUEZ-FEO JA, GARCIA-COLIS E, GOMEZ J, LOPEZ-BLAYA A et al. Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1-receptor blocker doxazosin. J Hypertens 2002; 20: 463-470.
23. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
24. MAGGIO B, DAIDONE G, RAFFA D, PLESCIS S, MANTIONE L et al. Synthesis and pharmacological study of ethyl 1-methyl-5-(substituted 3,4-dihydro-4- oxoquinazolin-3-yl)-1H-pyrazole-4-acetates. Europ J Med Chem 2001; 36: 737-742.
25. MARON DM, AMES BN. Revised methods for Salmonella mutagenicity test. Mutat Res 1983; 113: 173-215.
26. MAYER-KUCKUK P, BANERJEE D, MALHOTRA S, DOUBROVIN M, IWAMOTO M et al. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc Nat Acad Sci 2002; 99: 3400-3405.
27. MUCCI-LORUSSO P, POLIN L, BISSERY M, VALERIOTE F, PLOWMAN J et al. Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs 1989; 7: 295-306.
28. PANDEYA SN, SRIRAM D, NATH G, DE CLERCQ E. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharm Acta Helv 1999; 74: 11-17.
29. PARK SY, SEOL DW. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem. Biophys Res Commun 2002; 295: 515-518.
30. PISHA E, CHAI H, LEE IS, CHAGWEDERA TE, FARNSWORTH NR et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Med 1995; 1: 1046-1051.
31. RENAULT J, GIORGI-RENAULT S, BARON M, MAILLIET P, PAOLETTI C et al. Heterocyclic quinones. 4. A new nhighly cytotoxic drug: 6,7-bis(1-aziridinyl)-5, 8-quinazolinedione. J Med Chem 1983; 12: 1715-1719.
32. SINGH SK, PALIWAL JK, GROVER PK, GUPTA RC. Quantification of 2,3-dihydro-7- methoxypyrrolo-[2,1-b]-quinazolin-9(1H)-one, a new antiallergic agent, by high-performance liquid chromatography in serum. J Chromatogr B Biomed Appl 1994; 658: 198-201.
33. SRIVASTAVA VK, PALIT V, AGARWAL V, SHANKER K. Antiparkinsonian activity and behavioural effects of newer quinazolinones. Pharmacol Res Commun 1987; 19: 617-628.
34. STANKOVSKÝ Š, ŠPIRKOVÁ K. Amidinoyl isothiocyanates in the synthesis of condensed heterocycles: Tetrazolo- azidoazodomethine tautomerism in substituted tetrazolo[1,5-c] quinazolines. Monatshefte für Chemie 1991; 122: 849-852.
35. STEVENS GJ, MCQUEEN CHA. Species variation in the genotoxicity of batracylin. Toxicol Appl Pharmacol 1994; 126: 39-44.
36. STEVENS GJ, LAVOIE EJ, MCQUEEN CA. The role of acetylation in the mutagenicity of the antitumor agent, batracylin. Carcinogenesis 1996; 17: 115-119.
37. TAKIMO CH. Antifolates in clinical development. Semin Oncol 1997; 24: 18-51.
38. TAMURA T. Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors. Nippon Geka Gakkai Zasshi 2002; 103: 233-236.